Table 1

Baseline demographic and clinical characteristics among patients with genotype 2 (GT2) infection who completed therapy with sofosbuvir (SOF) and ribavirin (RBV)

Overall cohort Cirrhotics
CharacteristicSOF plus RBV for 12 weeks (n=283)SOF plus RBV for 16 weeks (n=38)Total (n=321)SOF plus RBV for 12 weeks (n=62)SOF plus RBV for 16 weeks (n=24)Total (n=86)
Median age (range), years59.0 (21–80)62.5 (30–78)59.0 (21–80)60 (40–78)62 (46–78)60.5 (40–78)
 18–3922 (7.8%)2 (5.3%)24 (7.5%)0 (0.0%)0 (0.0%)0 (0.0%)
 40–64202 (71.4%)22 (57.9%)224 (69.8%)49 (79.0%)16 (66.7%)65 (75.6%)
 65+59 (20.8%)14 (36.8%)73 (22.7%)13 (21%)8 (33.3%)21 (24.4%)
Male sex, n (%)174 (61.5%)22 (57.9%)196 (61.1%)40 (64.5%)14 (58.3%)54 (62.8%)
Race, n (%)
 White243 (85.9%)33 (86.8%)276 (86.0%)55 (88.7%)22 (91.7%)77 (89.5%)
 Black16 (5.7%)2 (5.3%)18 (5.6%)2 (3.2%)0 (0.0%)2 (2.3%)
 Other24 (8.5%)3 (7.9%)27 (8.4%)5 (8.1%)2 (8.3%)7 (8.1%)
 Hispanic ethnicity, n (%)22 (7.8%)5 (13.2%)27 (8.4%)7 (11.3%)3 (12.5%)10 (11.6%)
Prior HCV treatment, n (%)
 Naive205 (72.4%)18 (47.4%)223 (69.5%)32 (51.6%)7 (29.2%)39 (45.3%)
 Experienced78 (27.6%)20 (52.6%)98 (30.5%)30 (48.4%)17 (70.8%)47 (54.7%)
Cirrhosis, n (%)62 (21.9%)24 (63.2%)86 (26.8%)62/62 (100%)24/24 (100%)86/86 (100%)
History of hepatic decompensation, n (%)28 (9.9%)12 (31.6%)40 (12.5%)25 (40.3%)11 (45.8%)36 (41.9%)
MELD≥10 (among cirrhotics)*17/43 (39.5%)11/19 (57.9%)28/62 (45.2%)17/43 (39.5%)11/19 (57.9%)28/62 (45.2%)
HCV GT2 subtype
 2a18 (6.4%)3 (7.9%)21 (6.5%)3 (4.8%)2 (8.3%)5 (5.8%)
 2b125 (44.2%)22 (57.9%)147 (45.8%)31 (50.0%)13 (54.2%)44 (51.2%)
 2c2 (0.7%)0 (0.0%)2 (0.6%)0 (0.0%)0 (0.0%)0 (0.0%)
 2d1 (0.4%)0 (0.0%)1 (0.3%)0 (0.0%)0 (0.0%)0 (0.0%)
 Not reported137 (48.4%)13 (34.2%)150 (46.7%)28 (41.2%)9 (37.5%)37 (43%)
 EU patients11 (4.8%)1 (2.7%)12 (3.8%)4 (6.4%)1 (4.2%)5 (5.8%)
HCV RNA (median), log10 IU/mL6.36.46.35.96.05.9
Total bilirubin, median (range), mg/dL0.6 (0.1–6.2)0.8 (0.3–5.5)0.6 (0.1–6.2)1.0 (0.2–6.2)1.2 (0.3–5.5)1.0 (0.2–6.2)
Albumin, median (range), g/dL4.2 (2.2–5.4)3.8 (2.6–4.6)4.2 (2.2–5.4)3.7 (2.2–4.9)3.7 (2.6–4.5)3.7 (2.2–4.9)
ALT, median (range), IU/L53.0 (9.0–554.0)62.5 (20.0–428.0)53.0 (9.0–554.0)49.0 (24.0–278.0)81.0 (20.0–428.0)64.0 (20.0–428.0)
Platelet count, median (range) (×103)/µL189 (35.0–407.0)111 (34.0–302.0)185 (34.0–407.0)105.5 (35.0–307.0)77 (34.0–229.0)100 (34.0–307.0)
  • *In patients with available score.

  • ALT, alanine-aminotransferase; EU, European Union; MELD, model for end-stage liver disease.